DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers

NCT06132113 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

55

Enrollment

INDUSTRY

Sponsor class

Conditions

Neuroendocrine Neoplasms

Interventions

DRUG: BI 764532
DRUG: Carboplatin
DRUG: Etoposide
DRUG: Cisplatin

Sponsor

Boehringer Ingelheim